Mirikizumab is associated with improvements in bowel urgency and quality of life in moderately-to-severely active ulcerative colitis: 28-week phase 3b results from the LUCENT-URGE trial.
Overview & Synopsis
Open access biomedical research article published in Crohns Colitis 360.
Indexed from repository: PubMed Central
(
pmc.ncbi.nlm.nih.gov)
Keyboard Shortcuts:
← / → for pages • + / - for zoom • 0 to fit width
Powered by Mozilla PDF.js v3.11
Document Information
| Document Title | Mirikizumab is associated with improvements in bowel urgency and quality of life in moderately-to-severely active ulcerative colitis: 28-week phase 3b results from the LUCENT-URGE trial. |
|---|---|
| Author / Organization | Long M, Laharie D, Rogler G, Navabi S, Vadhariya A, Eastman WJ, Tian T, Bleakman AP, Armuzzi A |
| Subject & Discipline | Crohns Colitis 360 |
| Categories | Medicine & Health |
| Publication Year | 2026 |
| License / Rights | Open Access / Creative Commons |
| Resource Verification | Listed PDF (Verification Pending) |
| Original Host Website |
PubMed Central
(pmc.ncbi.nlm.nih.gov)
|
| File Format | application/pdf (Portable Document Format) |
| Language | EN |
| Catalog ID | DOC-10499 |
| Original Source Link | Visit Source Page on pmc.ncbi.nlm.nih.gov » |